Li Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li Yan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chad H. Hochberg
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University , Baltimore, MD
3 shared publications - Theodore John Iwashyna
Department of Pulmonology and Critical Care Johns Hopkins School of Medicine Baltimore Maryland USA
3 shared publications - Anica C. Law
The Pulmonary Center, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine , Boston, MA
2 shared publications - Joseph F. Levy
Department of Health Policy and Management Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA
2 shared publications - Khyzer B. Aziz
School of Medicine, Johns Hopkins University, Baltimore, MD, USA
2 shared publications - Nicholas A. Bosch
The Pulmonary Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA
2 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38
Antifungal use with and without fungal diagnoses among patients with septic shock in a retrospective multicenter cohort
INTRODUCTION Sepsis caused by fungal organisms is associated with higher mortality and longer time to diagnosis.(,) Estimates of the incidence of fungal infections among patients with sepsis in the United States have not been reported since 2000 and did not specifically address those with septic shock.() There have since been changes in sepsis management and […] INTRODUCTION Sepsis caused by fungal organisms is associated with higher mortality and longer time to diagnosis.(,) Estimates of the incidence of fungal infections among patients with sepsis in the United States have not been reported since 2000 and did not specifically address those with septic shock.() There have since been changes in sepsis management and […]
- 25 August 2026
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38
Open AccessAntifungal use with and without fungal diagnoses among patients with septic shock in a retrospective multicenter cohort
INTRODUCTION Sepsis caused by fungal organisms is associated with higher mortality and longer time to diagnosis.(,) Estimates of the incidence of fungal infections among patients with sepsis in the United States have not been reported since 2000 and did not specifically address those with septic shock.() There have since been changes in sepsis management and […] INTRODUCTION Sepsis caused by fungal organisms is associated with higher mortality and longer time to diagnosis.(,) Estimates of the incidence of fungal infections among patients with sepsis in the United States have not been reported since 2000 and did not specifically address those with septic shock.() There have since been changes in sepsis management and […]
- Open Access
Antifungal use with and without fungal diagnoses in septic shock across U.S. hospitals, 2022-2024
Septic shock caused by fungal organisms is characterized by high mortality and diagnostic complexity. We used the Premier Healthcare Database to characterize antifungal use and fungal diagnoses among adults with septic shock requiring vasopressors admitted between October 2022 through July 2024. Among 12.8 million admission at 886 hospitals, 554,948 met septic shock criteria and were included for analysis. A fungal diagnosis was established in 11,405 (2.1%) of encounters; of these, 3,565 (31.3%) received intravenous antifungal therapy within one day of vasopressor initiation. In the overall cohort, antifungal therapy was initiated in 29,824 (5.5%) within one day of vasopressor initiation; of these, 3,656 (12.2%) were ultimately diagnosed with a fungal infection. In the 116 hospitals reporting microbiological data, a subgroup of 489 encounters with septic shock and culture-confirmed candidemia was identified. In this subgroup, intravenous antifungal therapy was initiated in 43.8% within one day, 63.8% within three days, and 78.9% within seven days. These findings highlight a profound decoupling between fungal diagnosis and treatment—few patients receiving antifungals were diagnosed with an infection that would be treated by these agents, while less than half of patients with septic shock and candidemia received timely treatment. Strategies for greater precision in empiric antifungal use in septic shock are needed to improve safety, stewardship, and outcomes.
Open AccessAntifungal use with and without fungal diagnoses in septic shock across U.S. hospitals, 2022-2024
Septic shock caused by fungal organisms is characterized by high mortality and diagnostic complexity. We used the Premier Healthcare Database to characterize antifungal use and fungal diagnoses among adults with septic shock requiring vasopressors admitted between October 2022 through July 2024. Among 12.8 million admission at 886 hospitals, 554,948 met septic shock criteria and were included for analysis. A fungal diagnosis was established in 11,405 (2.1%) of encounters; of these, 3,565 (31.3%) received intravenous antifungal therapy within one day of vasopressor initiation. In the overall cohort, antifungal therapy was initiated in 29,824 (5.5%) within one day of vasopressor initiation; of these, 3,656 (12.2%) were ultimately diagnosed with a fungal infection. In the 116 hospitals reporting microbiological data, a subgroup of 489 encounters with septic shock and culture-confirmed candidemia was identified. In this subgroup, intravenous antifungal therapy was initiated in 43.8% within one day, 63.8% within three days, and 78.9% within seven days. These findings highlight a profound decoupling between fungal diagnosis and treatment—few patients receiving antifungals were diagnosed with an infection that would be treated by these agents, while less than half of patients with septic shock and candidemia received timely treatment. Strategies for greater precision in empiric antifungal use in septic shock are needed to improve safety, stewardship, and outcomes.
- Open Access
- 20 February 2026
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38, e20260366
Patterns and outcomes of real-world high-flow nasal cannula use: a multi-hospital retrospective cohort study
Objective: To characterize real-world high-flow nasal cannula use and outcomes. Methods: A retrospective observational study using an electronic health record registry of all adult patients in a five-hospital system between 2017 – 2025. We identified all high-flow nasal cannula episodes, defined as periods of high-flow nasal cannula use containing breaks no longer than 6 […] ABSTRACT Objective: To characterize real-world high-flow nasal cannula use and outcomes. Methods: A retrospective observational study using an electronic health record registry of all adult patients in a five-hospital system between 2017 – 2025. We identified all high-flow nasal cannula episodes, defined as periods of high-flow nasal cannula use containing breaks no longer than 6 […]
- 20 February 2026
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38, e20260366
Open AccessPatterns and outcomes of real-world high-flow nasal cannula use: a multi-hospital retrospective cohort study
Objective: To characterize real-world high-flow nasal cannula use and outcomes. Methods: A retrospective observational study using an electronic health record registry of all adult patients in a five-hospital system between 2017 – 2025. We identified all high-flow nasal cannula episodes, defined as periods of high-flow nasal cannula use containing breaks no longer than 6 […] ABSTRACT Objective: To characterize real-world high-flow nasal cannula use and outcomes. Methods: A retrospective observational study using an electronic health record registry of all adult patients in a five-hospital system between 2017 – 2025. We identified all high-flow nasal cannula episodes, defined as periods of high-flow nasal cannula use containing breaks no longer than 6 […]